

Annette Langer-Gould, MD, PhD is the Regional Lead for Clinical and Translational Neuroscience for the Southern California Permanente Medical Group and practicing MS specialist at Los Angeles Medical Center. In her current role, she leads a team in Kaiser Permanente that develops, implements, and evaluates programs to provide high quality affordable care for individuals with MS and other neurological diseases. She completed her residency, PhD in epidemiology and post-doctoral fellowship at Stanford University. She has been studying different aspects of MS susceptibility and prognosis for over 15 years. Dr. Langer-Gould's epidemiologic research focuses on the interplay between modifiable factors including race/ethnicity, vitamin D and sun exposure with genotype in determining MS susceptibility and prognosis. In collaboration with the Swedish MS Registry, she is also studying the comparative effectiveness of rituximab and other MS treatments. She has received grant support and awards from the National Institutes of Health, Patient Centered Outcomes Research Institute, and the National MS Society. She has served on committees and advisory panels for the National Institutes of Health, Institute of Medicine, American Academy of Neurology, and the National MS Society. She currently serves as a voting member on the California Technology Assessment Forum, a core program of the Institute for Clinical and Economic Review.